Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 11Blastic Plasmacytoid Dendritic Cell Neoplasm 6Leukemia, Myelomonocytic, Chronic 3Recurrence 2Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Hematologic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Neoplasm, Residual 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, B-Cell 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hodgkin Disease 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 155Dexamethasone 141Rituximab 85fludarabine 80Lenalidomide 72Cytarabine 70Bortezomib 65fludarabine phosphate 63Gemcitabine 62venetoclax 55pomalidomide 53Etoposide 53pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × tagraxofusp × Clear all
NCT04342962 2025-01-30

Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2 Terminated
25 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT02661022 2024-04-17

SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

Stemline Therapeutics, Inc.

Phase 1/2 Terminated
9 enrolled 13 charts
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡